Drug that could reduce lung cancer deaths by 51%

Accordingly, early stage lung cancer patients who took Tagrisso every day for 3 years, 1 pill per day, reduced their risk of death by 51%, according to NBCNews (USA) .

The trial’s lead investigator, Professor Roy Herbst, PhD, deputy director of the Yale Cancer Center (USA), said it was the first time a drug to treat early-stage lung cancer had saved so many patients. Osimertinib, sold under the brand name Tagrisso, targets a receptor that has properties that activate the growth of cancer cells.

The drug Osimertinib, sold under the brand name Tagrisso, targets a receptor that has properties that trigger the growth of cancer cells.

Professor Herbst said: Thanks to this drug, many patients are being cured. And the treatment of lung cancer is more advanced than ever.

Professor Herbst also said the trial results were "twice as good as expected", and the potential for life-saving was astonishing!

In an international study of 682 lung cancer patients from more than 20 countries across the United States, Europe, South America, Asia and the Middle East, about half of the participants were given the drug daily for three years, while the other half received a placebo as a control.

These patients had stage 1, 2, and 3 non-small cell lung cancer.

As a result, five years after the onset of the disease, 88% of patients taking the drug were still alive, compared with 78% in the placebo group.

Researchers found that the drug reduced the risk of dying from lung cancer by 51%.

Researchers found that the drug reduced the risk of dying from lung cancer by 51 percent, according to NBC News.

Tagrisso has been approved in more than 100 countries, and the US Food and Drug Administration (FDA) approved the drug in 2015 for people with advanced lung cancer that has not worked with other treatments.

Then, in 2020, the agency approved Tagrisso for early-stage patients.

Three years ago, Dr. Herbst's team showed that Tagrisso could stop tumors from coming back and prevent cancer from spreading to the brain, liver and bones.

Dr. Charu Aggarwal, associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (USA), although not involved in the study, also said: We know this drug is effective. But now, the drug can actually help patients live longer, according to NBC News.

Source link: https://thanhnien.vn/dot-pha-loai-thuoc-co-kha-nang-giam-51-ca-tu-vong-do-ung-thu-phoi-185230609193728914.htm